Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis

Citation
S. Fanali et al., Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis, ELECTROPHOR, 21(12), 2000, pp. 2432-2437
Citations number
25
Categorie Soggetti
Chemistry & Analysis
Journal title
ELECTROPHORESIS
ISSN journal
01730835 → ACNP
Volume
21
Issue
12
Year of publication
2000
Pages
2432 - 2437
Database
ISI
SICI code
0173-0835(200007)21:12<2432:QCOBAC>2.0.ZU;2-L
Abstract
In modern practice, the treatment of Parkinson's disease and syndrome is ca rried out using pharmaceutical formulations containing a combination of lev odopa and a decarboxylation inhibitor (carbidopa or benserazide). Two pharm aceutical formulations were quantified by capillary zone electrophoresis us ing two procedures which differed only in the kind of background electrolyt e used. One procedure used a 25 mM phosphate buffer, pH 2.5, while the seco nd one used a 25 mM berate buffer, pH 8.5. The electrophoretic analysis was carried out using an uncoated fused- silica capillary, a separation voltag e of 20 kV with currents typically less than 60 mu A, and spectrophotometri c detection at 205 nm. Calibration curves were performed for levodopa (conc entration range 1-100 mu g/mL), for carbidopa and benserazide (1-50 mu g/mL ), and the plots of the peak area versus concentration were found to be lin ear with a correlation coefficient better than 0.9990. Satisfactory results were obtained when commercial tablets were analyzed in terms of accuracy ( 98-102%), repeatability (0.6-2.0%), and intermediate precision (1.1-2.6%).